The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform

Haruhiro Inoue - One of the best experts on this subject based on the ideXlab platform.

  • Endoscopic Mucosal Resection in the Esophagus
    Laparoscopic Surgery of the Abdomen, 2020
    Co-Authors: Haruhiro Inoue
    Abstract:

    Mucosal Cancer in the esophagus generally has no risk of lymph node metastasis. It is cured by EMR, which provides a resected specimen for histopathological analysis.

  • Mucosal Cancer of the esophagus that presented significant changes of endoscopic findings in repeated observations
    Digestive Endoscopy, 2020
    Co-Authors: Tatsuya Yoshida, Haruhiro Inoue, Makoto Obata, Philip W. Y. Chiu, Hiroshi Kawachi, Shinsuke Usui, Hitoshi Satodate, Shinei Kudo
    Abstract:

    We report our experience of a very unique case with superficial esophageal Cancer presenting significant changes of endoscopic findings within 2 months. A 60-year-old man was referred to our hospital because of abrupt and severe chest pain. Upper gastrointestinal endoscopy demonstrated a shallow depressed lesion covered with whitish slough at the middle thoracic esophagus, which was identified as an unstained area by iodine dye spray. In the lower thoracic esophagus, we did not detect any abnormality during initial endoscopy. Although we diagnosed this lesion as atypical esophagitis, histological examination of the biopsy specimen confirmed squamous cell carcinoma. Furthermore, the endoscopic appearance showed dramatic changes over 2 months. The initial lesion at the middle thoracic esophagus gradually diminished, while the mucosa became slightly clouded in the lower thoracic esophagus. This cloudy area became unstained after iodine dye spray. The unstained area of the lower thoracic esophagus gradually spread. We performed four endoscopic Mucosal resections separately in 4 days over a period of 5 months. All of the specimens were shown to be squamous cell carcinoma on histological examination. The patient is on endoscopic surveillance and over a period of 1 year, there has been no recurrence.

  • endoscopic Mucosal resection endoscopic subMucosal dissection and beyond full layer resection for gastric Cancer with nonexposure technique clean net
    Surgical Oncology Clinics of North America, 2012
    Co-Authors: Haruhiro Inoue, Haruo Ikeda, Toshihisa Hosoya, Akira Yoshida, Manabu Onimaru, Michitaka Suzuki, Shinei Kudo
    Abstract:

    : Mucosal Cancer in the gastrointestinal tract generally has low risk of lymph node metastasis. Endoscopic Mucosal resection (EMR) and endoscopic subMucosal dissection (ESD) are techniques of local excision of neoplasia confined to the Mucosal layer. Specimens from EMR/ESD contribute to several diagnoses, and histologic results affect treatment decisions. A combined laparoscopic and endoscopic approach to neoplasia with a nonexposure technique allows full-thickness resection of the stomach wall without exposing the gastric lumen to the peritoneal cavity, preventing Cancer cell dissemination to the peritoneal cavity. This article reviews EMR/ESD and describes a new full-thickness resection method using the nonexposure technique (CLEAN-NET).

  • endoscopic Mucosal resection endoscopic subMucosal dissection and beyond full layer resection for gastric Cancer with nonexposure technique clean net
    Surgical Oncology Clinics of North America, 2012
    Co-Authors: Haruhiro Inoue, Haruo Ikeda, Toshihisa Hosoya, Akira Yoshida, Manabu Onimaru, Michitaka Suzuki, Shinei Kudo
    Abstract:

    Surgical resection of gastrointestinal Cancers is often associated with significant morbidity and mortality. Therefore, methods for endoscopic Cancer resection have been sought. With adequate staging techniques, endoscopic resection of early lesions looks promising. In surgically resected specimens, intraMucosal Cancer has an extremely small risk of lymph node metastasis. Therefore, endoscopic resection of Mucosal Cancer is potentially curable without lymph node dissection. EMR/ESD is a technique of local excision of neoplastic lesions confined to the Mucosal layer. However, EMR is a snare-based resection method similar to endoscopic polypectomy. The resected margin is often difficult to control accurately. In contrast, ESD is a knife-based dissection procedure in which the resected margin is first

  • Clinicopathologic analysis of lymph node metastasis in surgically resected superficial Cancer of the thoracic esophagus.
    Diseases of The Esophagus, 2000
    Co-Authors: M. Endo, Kunihide Yoshino, Tatsuyuki Kawano, Kagami Nagai, Haruhiro Inoue
    Abstract:

    We examined lymph node metastasis clinicopathologically in 236 cases of superficial Cancer (T1, Tis) of the thoracic esophagus surgically resected at our department without adjuvant treatment. Mucosal Cancer was observed in 112 cases (47%) and subMucosal Cancer in 124 cases (53%). Lymph node metastasis was present in 3% of Mucosal Cancer cases and 41% of subMucosal Cancer cases. By the recent pathologic subclassification of the extent of the Cancerous invasion in superficial esophageal Cancer, Mucosal Cancer and subMucosal Cancer were each divided into three subtypes according to the extent of invasion, i.e. m1, m2, m3, sm1, sm2 and sm3 Cancers. There was no case of lymph node metastasis in m1 and m2 cases, but it was observed in 8% of m3 cases, in 11% of sm1 cases, in 30% of sm2 cases and in 61% of sm3 cases. The number of involved nodes was three or less in m3 and sm1 cases, however four or more involved nodes were observed in 14% of sm2 cases and in 24% of sm3 cases. Positive lymph nodes were found only in the mediastinum in m3 and sm1 cases. On the contrary, they were found extensively in the mediastinum, the abdomen and the neck and in two or more regions in 27% of sm2 cases and in 38% of sm3 cases. Considering the location of positive nodes, the recurrent nerve lymph nodes were most frequently involved, followed by the cardiac lymph nodes. A similar tendency was observed in cases with single node metastasis. The 5-year survival rate of cases from m1 to sm1 was similar. That of sm3 cases was significantly worse than that of other groups. Based on the clinical results, the therapeutic guidelines for superficial Cancer of the thoracic esophagus are considered to be as follows: (i) in m1 and m2 Cancer, endoscopic Mucosal resection is generally indicated in principle, although transhiatal esophagectomy may be indicated in some cases; (ii) in m3 and sm1 Cancer, endoscopic Mucosal resection is performed initially, then subsequent treatment is selected if necessary; (iii) in sm2 and sm3 Cancer, conventional transthoracic esophagectomy with systematic lymph node dissection is indicated.

Shiran Ferber - One of the best experts on this subject based on the ideXlab platform.

  • immunology guided biomaterial design for Mucosal Cancer vaccines
    Advanced Materials, 2020
    Co-Authors: Shiran Ferber, Rodrigo J Gonzalez, Alexander M Cryer, Ulrich H Von Andrian, Natalie Artzi
    Abstract:

    : Cancer of Mucosal tissues is a major cause of worldwide mortality for which only palliative treatments are available for patients with late-stage disease. Engineered Cancer vaccines offer a promising approach for inducing antitumor immunity. The route of vaccination plays a major role in dictating the migratory pattern of lymphocytes, and thus vaccine efficacy in Mucosal tissues. Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vaccination route. However, this induces marginal Mucosal protection in the absence of tissue-specific imprinting signals. To circumvent this, the Mucosal route can be utilized, however degradative Mucosal barriers must be overcome. Hence, vaccine administration route and selection of materials able to surmount transport barriers are important considerations in Mucosal Cancer vaccine design. Here, an overview of Mucosal immunity in the context of Cancer and Mucosal Cancer clinical trials is provided. Key considerations are described regarding the design of biomaterial-based vaccines that will afford antitumor immune protection at Mucosal surfaces, despite limited knowledge surrounding Mucosal vaccination, particularly aided by biomaterials and mechanistic immune-material interactions. Finally, an outlook is given of how future biomaterial-based Mucosal Cancer vaccines will be shaped by new discoveries in Mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and material-immune system interplay.

  • Immunology‐Guided Biomaterial Design for Mucosal Cancer Vaccines
    Advanced Materials, 2019
    Co-Authors: Shiran Ferber, Rodrigo J Gonzalez, Alexander M Cryer, Ulrich H Von Andrian, Natalie Artzi
    Abstract:

    : Cancer of Mucosal tissues is a major cause of worldwide mortality for which only palliative treatments are available for patients with late-stage disease. Engineered Cancer vaccines offer a promising approach for inducing antitumor immunity. The route of vaccination plays a major role in dictating the migratory pattern of lymphocytes, and thus vaccine efficacy in Mucosal tissues. Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vaccination route. However, this induces marginal Mucosal protection in the absence of tissue-specific imprinting signals. To circumvent this, the Mucosal route can be utilized, however degradative Mucosal barriers must be overcome. Hence, vaccine administration route and selection of materials able to surmount transport barriers are important considerations in Mucosal Cancer vaccine design. Here, an overview of Mucosal immunity in the context of Cancer and Mucosal Cancer clinical trials is provided. Key considerations are described regarding the design of biomaterial-based vaccines that will afford antitumor immune protection at Mucosal surfaces, despite limited knowledge surrounding Mucosal vaccination, particularly aided by biomaterials and mechanistic immune-material interactions. Finally, an outlook is given of how future biomaterial-based Mucosal Cancer vaccines will be shaped by new discoveries in Mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and material-immune system interplay.

Natalie Artzi - One of the best experts on this subject based on the ideXlab platform.

  • immunology guided biomaterial design for Mucosal Cancer vaccines
    Advanced Materials, 2020
    Co-Authors: Shiran Ferber, Rodrigo J Gonzalez, Alexander M Cryer, Ulrich H Von Andrian, Natalie Artzi
    Abstract:

    : Cancer of Mucosal tissues is a major cause of worldwide mortality for which only palliative treatments are available for patients with late-stage disease. Engineered Cancer vaccines offer a promising approach for inducing antitumor immunity. The route of vaccination plays a major role in dictating the migratory pattern of lymphocytes, and thus vaccine efficacy in Mucosal tissues. Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vaccination route. However, this induces marginal Mucosal protection in the absence of tissue-specific imprinting signals. To circumvent this, the Mucosal route can be utilized, however degradative Mucosal barriers must be overcome. Hence, vaccine administration route and selection of materials able to surmount transport barriers are important considerations in Mucosal Cancer vaccine design. Here, an overview of Mucosal immunity in the context of Cancer and Mucosal Cancer clinical trials is provided. Key considerations are described regarding the design of biomaterial-based vaccines that will afford antitumor immune protection at Mucosal surfaces, despite limited knowledge surrounding Mucosal vaccination, particularly aided by biomaterials and mechanistic immune-material interactions. Finally, an outlook is given of how future biomaterial-based Mucosal Cancer vaccines will be shaped by new discoveries in Mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and material-immune system interplay.

  • Immunology‐Guided Biomaterial Design for Mucosal Cancer Vaccines
    Advanced Materials, 2019
    Co-Authors: Shiran Ferber, Rodrigo J Gonzalez, Alexander M Cryer, Ulrich H Von Andrian, Natalie Artzi
    Abstract:

    : Cancer of Mucosal tissues is a major cause of worldwide mortality for which only palliative treatments are available for patients with late-stage disease. Engineered Cancer vaccines offer a promising approach for inducing antitumor immunity. The route of vaccination plays a major role in dictating the migratory pattern of lymphocytes, and thus vaccine efficacy in Mucosal tissues. Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vaccination route. However, this induces marginal Mucosal protection in the absence of tissue-specific imprinting signals. To circumvent this, the Mucosal route can be utilized, however degradative Mucosal barriers must be overcome. Hence, vaccine administration route and selection of materials able to surmount transport barriers are important considerations in Mucosal Cancer vaccine design. Here, an overview of Mucosal immunity in the context of Cancer and Mucosal Cancer clinical trials is provided. Key considerations are described regarding the design of biomaterial-based vaccines that will afford antitumor immune protection at Mucosal surfaces, despite limited knowledge surrounding Mucosal vaccination, particularly aided by biomaterials and mechanistic immune-material interactions. Finally, an outlook is given of how future biomaterial-based Mucosal Cancer vaccines will be shaped by new discoveries in Mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and material-immune system interplay.

Hiroshi Yoshimura - One of the best experts on this subject based on the ideXlab platform.

  • Clinicopathologic Features of Superficial Esophageal Cancer: Results of Consecutive 100 Patients
    Annals of Surgical Oncology, 2008
    Co-Authors: Mitsuo Tachibana, Shoichi Kinugasa, Noriyuki Hirahara, Hiroshi Yoshimura
    Abstract:

    Background The depth of tumor penetration is a crucial factor in determining the prognosis of patients with esophageal carcinoma. Patients with superficial esophageal carcinoma (SEC) have a far more favorable clinical course compared with those with advanced Cancers. The outcome for patients with Mucosal Cancer is excellent with a 5-year survival rate exceeding 80%. On the other hand, subMucosal Cancer often metastasizes to regional and/or distant lymph nodes or other organs, and the prognosis of these patients are far from satisfactory. Methods Among 334 patients with esophageal Cancer who underwent surgery between December 1980 and December 2006, 100 patients (30%) had SEC confined to the epithelium, lamina propria mucosa, or submucosa. Patient and tumor characteristics of those 100 patients were studied. Results The prevalence of SEC has increased from 13% (8 of 61) in the initial 5-year period (1985–1989) to 44% (41 of 93) in the recent 7-year period (2000–2006). Subjective symptoms were present in 7 (14%) of 51 Mucosal Cancers and in 13 (27%) of 49 subMucosal Cancers. The remaining 80 patients (80%) had no subjective symptoms. Ninety-one patients (91%) were diagnosed to have the lesions by endoscopy at the time of screening for gastric problems, and only nine were detected by gastrointestinal series. Four of 51 patients with Mucosal Cancer had venous or lymph vessel invasion, and among those, only one (2%) had a solitary perigastric lymph node metastasis. In 49 patients with subMucosal Cancer, 35 (71%) had lymph vessel invasion, 28 (57%) had venous invasion, and 16 (33%) had lymph node metastases. In particular, 15 of 35 patients with positive lymph vessel invasion had lymph node metastasis, whereas only 1 of 14 with negative lymph vessel invasion had lymph node metastasis ( P < .05). Among 17 patients with nodal involvement, 4 patients with upper thoracic SEC had upper mediastinum and/or cervical nodal metastases, 11 patients with middle thoracic SEC had widespread upper and lower mediastinal and abdominal metastases, and 2 patients with lower thoracic SEC had lower and abdominal lymph node metastases. Seventy-nine patients were alive without recurrence at last follow-up. Five of 49 patients with subMucosal Cancer died of recurrent disease, and 4 of these developed regional nodal recurrence around the bilateral laryngeal recurrent nerves. Forty-two patients (42%) developed double Cancers during the follow-up period, and 5 died of a second Cancer. The 3- and 5-year survival rates of all 100 patients were 85% and 73%, and those disease-specific survival rates were 96% and 93%, respectively. The 3- and 5-year survival rates for patients with Mucosal Cancer were 89% and 83%, and those for subMucosal Cancer were 80%, and 64%, respectively. Conclusions Esophagectomy with extensive lymphadenectomy should be carried out particularly for upper thoracic subMucosal Cancer, whereas esophagectomy with moderate lymphadenectomy may be preferred for Mucosal Cancer. Patients with SEC should be examined for another primary Cancer preoperatively and periodically during follow-up.

  • Clinicopathologic Features of Superficial Esophageal Cancer: Results of Consecutive 100 Patients
    Annals of Surgical Oncology, 2007
    Co-Authors: Mitsuo Tachibana, Shoichi Kinugasa, Noriyuki Hirahara, Hiroshi Yoshimura
    Abstract:

    Background The depth of tumor penetration is a crucial factor in determining the prognosis of patients with esophageal carcinoma. Patients with superficial esophageal carcinoma (SEC) have a far more favorable clinical course compared with those with advanced Cancers. The outcome for patients with Mucosal Cancer is excellent with a 5-year survival rate exceeding 80%. On the other hand, subMucosal Cancer often metastasizes to regional and/or distant lymph nodes or other organs, and the prognosis of these patients are far from satisfactory.

  • Clinicopathological features of superficial squamous cell carcinoma of the esophagus
    American Journal of Surgery, 1997
    Co-Authors: Mitsuo Tachibana, Hiroshi Yoshimura, Shoichi Kinugasa, Naoki Hashimoto, Dipok Kumar Dhar, Naomi Monden, Naofumi Nagasue
    Abstract:

    background The depth of penetration is the crucial factor determining the prognosis of esophageal carcinoma patients. Patients with superficial esophageal carcinoma have a significantly favorable clinical course compared with those with advanced Cancers. The outcome for patients with Mucosal Cancer is excellent with a 5-year survival rate exceeding 80%. On the other hand, subMucosal Cancer often metastasizes to lymph nodes or other organs, and the prognosis of these patients is far from satisfactory. methods Among 165 patients with squamous cell carcinoma of the esophagus, surgically resected between December 1979 and April 1995, 30 patients (18.2%) had superficial esophageal carcinoma (SEC) confined to the epithelium, lamina propria mucosa, or submucosa. Disease profile and Clinicopathological characteristics of these 30 patients were studied. results The incidence of SEC has increased from 6.3% (2 of 32) in the first 5-year period (1979 to 1984) to 27.4% (20 of 73) in the recent 5-year period (1991 to 1995). Subjective symptoms were present in 2 (13.3%) with 15 Mucosal Cancers and in 4 (26.7%) with 15 subMucosal Cancers. The remaining 24 patients (80%) had no subjective symptoms. Twenty-two patients (73.3%) were diagnosed to have the lesions by endoscopic examination at the time of screening for gastric problems, and only 3 were detected by gastrointestinal series. None of the 15 patients with Mucosal Cancer had lymphatic invasion, venous invasion, or lymph node metastasis. On the other hand, in those with subMucosal Cancers, 9 (60%) had lymphatic invasion, 5 (33.3%) venous invasion, and 8 (53.3%) lymph node metastases. Twenty-two patients are alive without recurrence. The 3- and 5-year survival rates are 86.7% and 86.7% for patients with Mucosal Cancer and 72.2% and 65.0% for those with subMucosal Cancer, respectively. conclusion Esophagectomy with wide lymphadenectomy should be carried out for subMucosal Cancer, whereas esophagectomy with moderate lymphadenectomy can be preferred for Mucosal Cancer.

Ulrich H Von Andrian - One of the best experts on this subject based on the ideXlab platform.

  • immunology guided biomaterial design for Mucosal Cancer vaccines
    Advanced Materials, 2020
    Co-Authors: Shiran Ferber, Rodrigo J Gonzalez, Alexander M Cryer, Ulrich H Von Andrian, Natalie Artzi
    Abstract:

    : Cancer of Mucosal tissues is a major cause of worldwide mortality for which only palliative treatments are available for patients with late-stage disease. Engineered Cancer vaccines offer a promising approach for inducing antitumor immunity. The route of vaccination plays a major role in dictating the migratory pattern of lymphocytes, and thus vaccine efficacy in Mucosal tissues. Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vaccination route. However, this induces marginal Mucosal protection in the absence of tissue-specific imprinting signals. To circumvent this, the Mucosal route can be utilized, however degradative Mucosal barriers must be overcome. Hence, vaccine administration route and selection of materials able to surmount transport barriers are important considerations in Mucosal Cancer vaccine design. Here, an overview of Mucosal immunity in the context of Cancer and Mucosal Cancer clinical trials is provided. Key considerations are described regarding the design of biomaterial-based vaccines that will afford antitumor immune protection at Mucosal surfaces, despite limited knowledge surrounding Mucosal vaccination, particularly aided by biomaterials and mechanistic immune-material interactions. Finally, an outlook is given of how future biomaterial-based Mucosal Cancer vaccines will be shaped by new discoveries in Mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and material-immune system interplay.

  • Immunology‐Guided Biomaterial Design for Mucosal Cancer Vaccines
    Advanced Materials, 2019
    Co-Authors: Shiran Ferber, Rodrigo J Gonzalez, Alexander M Cryer, Ulrich H Von Andrian, Natalie Artzi
    Abstract:

    : Cancer of Mucosal tissues is a major cause of worldwide mortality for which only palliative treatments are available for patients with late-stage disease. Engineered Cancer vaccines offer a promising approach for inducing antitumor immunity. The route of vaccination plays a major role in dictating the migratory pattern of lymphocytes, and thus vaccine efficacy in Mucosal tissues. Parenteral immunization, specifically subcutaneous and intramuscular, is the most common vaccination route. However, this induces marginal Mucosal protection in the absence of tissue-specific imprinting signals. To circumvent this, the Mucosal route can be utilized, however degradative Mucosal barriers must be overcome. Hence, vaccine administration route and selection of materials able to surmount transport barriers are important considerations in Mucosal Cancer vaccine design. Here, an overview of Mucosal immunity in the context of Cancer and Mucosal Cancer clinical trials is provided. Key considerations are described regarding the design of biomaterial-based vaccines that will afford antitumor immune protection at Mucosal surfaces, despite limited knowledge surrounding Mucosal vaccination, particularly aided by biomaterials and mechanistic immune-material interactions. Finally, an outlook is given of how future biomaterial-based Mucosal Cancer vaccines will be shaped by new discoveries in Mucosal vaccinology, tumor immunology, immuno-therapeutic screens, and material-immune system interplay.